Key result
CGRP analogue SAX improves myocardial perfusion recovery ~3-fold vs placebo in a rat MI model.
Why the study?
Endogenous CGRP has cardioprotective effects via coronary vasodilation, but systemic administration induces peripheral vasodilation and positive chronotropic/inotropic effects, leaving its net effect on coronary perfusion unclear.
Does the α-calcitonin gene-related peptide analogue SAX improve myocardial perfusion recovery in rats with experimental myocardial infarction?
Does the α-calcitonin gene-related peptide analogue SAX improve myocardial perfusion recovery in rats with experimental myocardial infarction?
The CGRP analogue SAX significantly improved myocardial perfusion recovery after chronic coronary artery occlusion in a rat model of myocardial infarction.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for CGRP analogues in post-MI perfusion; leaves open any human translation.
Endogenous calcitonin gene-related peptide (CGRP) induces cardioprotective effects through coronary vasodilation. However, the systemic administration of CGRP induces peripheral vasodilation and positive chronotropic and inotropic effects. This study aims to examine the net effect on coronary perfusion of the systemically administered α-calcitonin gene-related peptide analogue, SAX, in rats during myocardial infarction. Forty Sprague-Dawley rats underwent myocardial infarction. Following left anterior descending artery occlusion, [99mTc]Tc-sestamibi was administered to determine the myocardial perfusion before treatment. Twenty minutes, 24 and 48 h after [99mTc]Tc-sestamibi injection, the rats were treated with either SAX or placebo. Final infarct size was determined three weeks later by [99mTc]Tc-sestamibi SPECT/CT scan. Thirty-one rats survived the surgery and 20 completed the follow-up SPECT/CT scan (SAX n = 12; Placebo n = 8). At baseline, there was no difference in size of perfusion defect between the groups (P = .88), but at follow-up the SAX group had improved myocardial recovery compared to the placebo group (P = .04), corresponding to a relative perfusion recovery of 55% in SAX-treated rats. The CGRP analogue, SAX, has a cardioprotective effect in this rat model of myocardial infarction, improving myocardial perfusion recovery after chronic occlusion of the coronary artery.
No takes yet. Share an insight, caveat, or question.
Bentsen et al. (2021) studied Myocardial Infarction (n=40). SAX (α-calcitonin gene-related peptide analogue) vs. Placebo was evaluated on Myocardial perfusion recovery (absolute difference in summed rest score [ΔSRS] between acute and follow-up scans) (p=0.04). The CGRP analogue SAX improved myocardial perfusion recovery compared to placebo in a rat model of myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: